Back to Search Start Over

Comprehensive evaluation of Impella RP ® in right ventricular failure.

Authors :
Montisci A
Sala S
Maj G
Cattaneo S
Pappalardo F
Source :
Future cardiology [Future Cardiol] 2022 Apr; Vol. 18 (4), pp. 285-298. Date of Electronic Publication: 2022 Feb 21.
Publication Year :
2022

Abstract

Right ventricular failure has a high morbidity and mortality in patients suffering from advanced heart failure, pulmonary hypertension, acute myocardial infarction after cardiac surgery and in left ventricular assist device patients. The Impella RP <superscript>®</superscript> catheter is a mechanical circulatory device, positioned from a venous femoral percutaneous access and passing through the tricuspid and pulmonary valves, reaches the pulmonary artery. Impella RP (Abiomed Inc., MA, USA) acts as a direct right ventricle bypass and it provides a flow up to 4.4 liters per minute, unloading the right ventricle. The main contraindications are: thrombi in the vena cava, right atrium and ventricle and pulmonary artery; mechanical tricuspid or pulmonary prostheses. In this review, the principles of operations, clinical applications and results of Impella RP are summarized and evaluated.

Details

Language :
English
ISSN :
1744-8298
Volume :
18
Issue :
4
Database :
MEDLINE
Journal :
Future cardiology
Publication Type :
Academic Journal
Accession number :
35187952
Full Text :
https://doi.org/10.2217/fca-2021-0075